Literature DB >> 27335365

Management of granulomatous lymphocytic interstitial lung disease in a patient with common variable immune deficiency.

Mohini Pathria1, Daniel Urbine1, Marc Stuart Zumberg1, Juan Guarderas1.   

Abstract

A 61-year-old woman presented with longstanding cough and progressive dyspnoea. She underwent an extensive evaluation and was diagnosed with common variable immunodeficiency (CVID) with granulomatous lymphocytic interstitial lung disease (GLILD). She was initially treated with subcutaneous immunoglobulin therapy, having declined intravenous immunoglobulin (IVIG) therapy. She also declined treatment with oral glucocorticoids. Over several months, she became increasingly symptomatic and developed increased pulmonary infiltrates, pleural effusions, mediastinal adenopathy, splenomegaly, pancytopenia and ascites. An interdisciplinary team composed of an immunologist, pulmonologist and haematologist deliberated over a therapeutic management approach. The patient received a recently reported immunotherapy regimen with azathioprine and rituximab. The therapy led to rapid improvement of her constitutional and respiratory symptoms, with clinical and radiographic improvement in her interstitial lung disease, lymphadenopathy, pleural effusions and ascites. This case report reviews the literature surrounding the diagnosis and management of GLILD. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27335365      PMCID: PMC4932434          DOI: 10.1136/bcr-2016-215624

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Lymphocytic interstitial pneumonia associated with common variable immunodeficiency resolved with intravenous immunoglobulins.

Authors:  N Arish; R Eldor; Y Fellig; N Bogot; U Laxer; U Izhar; A Rokach
Journal:  Thorax       Date:  2006-12       Impact factor: 9.139

2.  CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters.

Authors:  L J Maarschalk-Ellerbroek; P A de Jong; J M van Montfrans; J W J Lammers; A C Bloem; A I M Hoepelman; P M Ellerbroek
Journal:  J Clin Immunol       Date:  2014-06-21       Impact factor: 8.317

3.  Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID).

Authors:  Nicole M Chase; James W Verbsky; Mary K Hintermeyer; Jill K Waukau; Aoy Tomita-Mitchell; James T Casper; Sumit Singh; Kaushik S Shahir; William B Tisol; Melodee L Nugent; R Nagarjun Rao; A Craig Mackinnon; Lawrence R Goodman; Pippa M Simpson; John M Routes
Journal:  J Clin Immunol       Date:  2012-08-29       Impact factor: 8.317

4.  Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.

Authors:  Delphine Gobert; James B Bussel; Charlotte Cunningham-Rundles; Lionel Galicier; Agnès Dechartres; Alice Berezne; Bernard Bonnotte; Thierry DeRevel; Christophe Auzary; Roland Jaussaud; Claire Larroche; Alain LeQuellec; Marc Ruivard; Pascal Seve; Amar Smail; Jean-François Viallard; Bertrand Godeau; Olivier Hermine; Marc Michel
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

5.  Morbidity and mortality in common variable immune deficiency over 4 decades.

Authors:  Elena S Resnick; Erin L Moshier; James H Godbold; Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2011-12-16       Impact factor: 22.113

6.  Failure in antigen responses by T cells from patients with common variable immunodeficiency (CVID).

Authors:  A J Stagg; M Funauchi; S C Knight; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

7.  Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency.

Authors:  Christopher A Bates; Misoo C Ellison; David A Lynch; Carlyne D Cool; Kevin K Brown; John M Routes
Journal:  J Allergy Clin Immunol       Date:  2004-08       Impact factor: 10.793

8.  Granulomatous disease in common variable immunodeficiency.

Authors:  Omür Ardeniz; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2009-08-28       Impact factor: 3.969

9.  Bronchiolitis obliterans organizing pneumonia in common variable immunodeficiency syndrome.

Authors:  J Kaufman; R Komorowski
Journal:  Chest       Date:  1991-08       Impact factor: 9.410

Review 10.  Sarcoidosis and common variable immunodeficiency: similarities and differences.

Authors:  James W Verbsky; John M Routes
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

View more
  5 in total

1.  FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID).

Authors:  S Jolles; E Carne; M Brouns; T El-Shanawany; P Williams; C Marshall; P Fielding
Journal:  Clin Exp Immunol       Date:  2016-11-28       Impact factor: 4.330

2.  What Works When Treating Granulomatous Disease in Genetically Undefined CVID? A Systematic Review.

Authors:  Astrid C van Stigt; Willem A Dik; Lieke S J Kamphuis; Bas M Smits; Joris M van Montfrans; P Martin van Hagen; Virgil A S H Dalm; Hanna IJspeert
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

3.  Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey.

Authors:  Annick A J M van de Ven; Tiago M Alfaro; Alexandra Robinson; Ulrich Baumann; Anne Bergeron; Siobhan O Burns; Alison M Condliffe; Børre Fevang; Andrew R Gennery; Filomeen Haerynck; Joseph Jacob; Stephen Jolles; Marion Malphettes; Véronique Meignin; Tomas Milota; Joris van Montfrans; Antje Prasse; Isabella Quinti; Elisabetta Renzoni; Daiana Stolz; Klaus Warnatz; John R Hurst
Journal:  Front Immunol       Date:  2020-11-26       Impact factor: 7.561

4.  Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review.

Authors:  Olivia A C Lamers; Bas M Smits; Helen Louisa Leavis; Godelieve J de Bree; Charlotte Cunningham-Rundles; Virgil A S H Dalm; Hsi-En Ho; John R Hurst; Hanna IJspeert; Sabine M P J Prevaes; Alex Robinson; Astrid C van Stigt; Suzanne Terheggen-Lagro; Annick A J M van de Ven; Klaus Warnatz; Janneke H H M van de Wijgert; Joris van Montfrans
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

5.  Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

Authors:  Yulia Rodina; E Deripapa; O Shvets; A Mukhina; A Roppelt; D Yuhacheva; A Laberko; V Burlakov; D Abramov; G Tereshchenko; G Novichkova; Anna Shcherbina
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.